Use of non-HIV medication among people living with HIV and receiving antiretroviral treatment in Côte d’Ivoire, West Africa: A cross-sectional study

English version

Autoři: Mariam Mama Djima ^aff001; Didier Koumavi Ekouevi ^aff001; Jean-Pierre Gregoire ^aff003; Boris Tchounga ^aff001; Patrick Ahuatchi Coffie ^aff001; Viet-Thi Tran ^aff001; Franck Y. Touré ^aff001; Jocelyne Moisan ^aff003
Působiště autorů: PACCI, CHU Treichville, Abidjan, Côte d’Ivoire ^aff001; Institut Pasteur de Côte d’Ivoire, Abidjan, Côte d’Ivoire ^aff002; Faculté de pharmacie, Université Laval, Québec, Canada ^aff003; Centre Inserm U 1219, ISPED, Université Victor Segalen, Bordeaux, France ^aff004; Université de Lomé, Département de Santé Publique, Lomé, Togo ^aff005; Axe Santé des populations et pratiques optimales en santé, Centre de recherche du CHU de Québec–Université Laval, Québec, Canada ^aff006
Vyšlo v časopise: PLoS ONE 14(9)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0221335

Souhrn

Background

In Côte d’Ivoire, people living with HIV (PLHIV) have free access to antiretroviral therapy (ART) and cotrimoxazole. Yet, they may use other medications to treat non-HIV diseases. Scarce data are available regarding the use of non-HIV medications in Africa. This study describes the use of non-HIV medications and identifies the factors associated with their use by PLHIV on ART in Côte d’Ivoire.

Methods

A cross-sectional study was conducted in six HIV clinics in 2016. HIV-1-infected adults receiving ART for at least one year were eligible. A standardized questionnaire was used to collect demographics, HIV characteristics and medication use data. Associated factors were identified using a multivariate adjusted Poisson regression.

Results

A total of 1,458 participants (74% women) were enrolled. The median age was 44 years, and the median duration of ART was 81 months. A total of 696 (48%) participants reported having used at least one non-HIV medication. Among the 1,519 non-HIV medications used, 550 (36%) had not been prescribed and 397 (26%) were from the nervous system class. Individuals who were more likely to report the use of at least one non-HIV medication included those who had been treated in an Abidjan HIV clinic, had a high school education level, had a monthly income between 152 and 304 euros, had a poor perceived health status, had WHO advanced clinical stage, had used traditional medicine products and had not used cotrimoxazole.

Conclusion

Almost half PLHIV on ART reported using non-HIV medication. Further research is needed to assess whether the use of non-HIV medication is appropriate given about a third of those medications are not being prescribed.

Klíčová slova:

Biology and life sciences – Microbiology – Medical microbiology – Microbial pathogens – Viral pathogens – Immunodeficiency viruses – HIV – Retroviruses – Lentivirus – Organisms – Viruses – RNA viruses – Vaccination and immunization – Anatomy – Nervous system – Medicine and health sciences – Pathology and laboratory medicine – Pathogens – Immunology – Public and occupational health – Preventive medicine – Antiviral therapy – Diagnostic medicine – HIV diagnosis and management – Cardiology – Pharmaceutics – Drug therapy – Complementary and alternative medicine – Social sciences – Sociology – Education – Schools

Zdroje

1. Ford N, Ball A, Baggaley R, Vitoria M, Low-Beer D, Penazzato M, et al. The WHO public health approach to HIV treatment and care: looking back and looking ahead. The Lancet Infectious diseases. 2017. doi: 10.1016/S1473-3099(17)30482-6 29066132.

2. Who Health Organisation. Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011. c2012 [cited 2018 Jan 01]. Available from: http://www.unaids.org/sites/default/files/media_asset/20111130_UA_Report_en_1.pdf.

3. The Joint United Nations Programme on HIV and AIDS. UNAIDS Report on the Global AIDS Epidemic 2010.c2010. [cited 2018 Jan 31]. Available from: http://www.unaids.org/sites/default/files/media_asset/20101123_globalreport_en_1.pdf.

4. Blot M, Piroth L. [HIV infection in France in 2012: Reality, risks and challenges for a chronic multisystem disease]. Rev Mal Respir. 2012;29(6):785–92. S0761-8425(12)00128-3 [pii] doi: 10.1016/j.rmr.2011.10.974 22742465.

5. Harris M, Nosyk B, Harrigan R, Lima VD, Cohen C, Montaner J. Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future. AIDS research and treatment. 2012;2012:595762. doi: 10.1155/2012/595762 23193464; PubMed Central PMCID: PMC3502757.

6. Peters BS, Conway K. Therapy for HIV: past, present, and future. Adv Dent Res. 2011;23(1):23–7. Epub 2011/03/29. doi: 10.1177/0022034511399082 [pii]. 21441476.

7. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013. Epub 2013/10/25. S0140-6736(13)61809-7 [pii] doi: 10.1016/S0140-6736(13)61809-7 24152939.

8. Who Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach. June 2013.2013c [cited 2018 Jan 21]. Available from: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html.

9. Wilson MG, Chambers L, Bacon J, Rueda S, Ragan M3, Rourke SB. issues of comorbidity in HIV/AIDS: an overview of systematic reviews. Ontario HIV Treatment Network. 2010. 2010c. [cited 2018 Jan 25]. Available from: http://www.a-id.it/pdf/issues-of-comorbidity-in-hiv-aids-an-overview-of-systematic-reviews-roundtable-draft.pdf.

10. Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. Aids. 2008;22(7):841–8. doi: 10.1097/QAD.0b013e3282f7cb76 [pii]. 18427202.

11. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172. doi: 10.1136/bmj.a3172 [pii]. 19171560.

12. Palella FJ Jr., Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. Journal of acquired immune deficiency syndromes. 2006;43(1):27–34. doi: 10.1097/01.qai.0000233310.90484.16 16878047.

13. Lamas CC, Coelho LE, Grinsztejn BJ, Veloso VG. Community-acquired lower respiratory tract infections in HIV-infected patients on antiretroviral therapy: predictors in a contemporary cohort study. Infection. 2017. doi: 10.1007/s15010-017-1041-0 28660356.

14. Eholie SP, Ello FN, Coffie PA, Hema A, Minta DK, Sawadogo A. Effect of cotrimoxazole prophylaxis on malaria occurrence among HIV-infected adults in West Africa: the MALHIV Study. Trop Med Int Health. 2017. doi: 10.1111/tmi.12919 28653454.

15. World Health O, Unaids. Provisional WHO/UNAIDS recommendations on the use of contrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. Afr Health Sci. 2001;1(1):30–1. 12833907; PubMed Central PMCID: PMCPMC2704444.

16. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. Aids. 2008;22(15):1897–908. doi: 10.1097/QAD.0b013e32830007cd 18784453; PubMed Central PMCID: PMCPMC3816249.

17. Eholie SP, Tanon KA, Folquet-Amorissani M, Ouattara I, Aba YT, Traore-Ettiegne V, et al. [Impact of access to antiretroviral therapy in Cote d'Ivoire]. Med Trop (Mars). 2009; 69(5):520–4. 20025190.

18. Programme national de prise en charge médicale des personnes vivant avec l'infection. Rapport annuel d’activités 2011 du programme national de prise en charge médicale des personnes vivant avec l'infection du ministère de la santé et de la lutte contre le sida. c2011. [updated 2012 Nov 25; cited 2018 Jan 21]. Available from: http://www.pnpec.ci/doc/Rapport%20Annuel%20PNPEC%202011.pdf.

19. Beauliere A, Toure S, Alexandre PK, Kone K, Pouhe A, Kouadio B, et al. The financial burden of morbidity in HIV-infected adults on antiretroviral therapy in Cote d'Ivoire. PloS one. 2010;5(6):e11213. doi: 10.1371/journal.pone.0011213 20585454; PubMed Central PMCID: PMCPMC2887850.

20. Angwenyi V, Aantjes C, Kajumi M, De Man J, Criel B, Bunders-Aelen J. Patients experiences of self-management and strategies for dealing with chronic conditions in rural Malawi. PloS one. 2018;13(7):e0199977. doi: 10.1371/journal.pone.0199977 29965990; PubMed Central PMCID: PMCPMC6028088.

21. Seden K, Khoo SH, Back D, Byakika-Kibwika P, Lamorde M, Ryan M, et al. Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting. J Antimicrob Chemother. 2013;68(1):1–3. doi: 10.1093/jac/dks346 [pii]. 22915459.

22. Ajuoga E, Sansgiry SS, Ngo C, Yeh RF. Use/misuse of over-the-counter medications and associated adverse drug events among HIV-infected patients. Research in social & administrative pharmacy: RSAP. 2008;4(3):292–301. doi: 10.1016/j.sapharm.2007.08.001 18794039.

23. Kamekis A, Bertsias A, Moschandreas J, Petelos E, Papadakaki M, Tsiantou V, et al. Patients' intention to consume prescribed and non-prescribed medicines: A study based on the theory of planned behaviour in selected European countries. J Clin Pharm Ther. 2018;43(1):26–35. doi: 10.1111/jcpt.12601 28833330.

24. Aziz MM, Masood I, Yousaf M, Saleem H, Ye D, Fang Y. Pattern of medication selling and self-medication practices: A study from Punjab, Pakistan. PloS one. 2018;13(3):e0194240. doi: 10.1371/journal.pone.0194240 29566014; PubMed Central PMCID: PMCPMC5863987.

25. Moshabela M, Schneider H, Silal SP, Cleary SM. Factors associated with patterns of plural healthcare utilization among patients taking antiretroviral therapy in rural and urban South Africa: a cross-sectional study. BMC Health Serv Res. 2012;12:182. doi: 10.1186/1472-6963-12-182 22747971; PubMed Central PMCID: PMCPMC3465179.

26. Peltzer K, Preez NF, Ramlagan S, Fomundam H. Use of traditional complementary and alternative medicine for HIV patients in KwaZulu-Natal, South Africa. BMC Public Health. 2008;8:255. doi: 10.1186/1471-2458-8-255 1471-2458-8-255 [pii]. 18652666; PubMed Central PMCID: PMC2503977.

27. Ranzani A, Oreni L, Agro M, van den Bogaart L, Milazzo L, Giacomelli A, et al. Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older. Journal of acquired immune deficiency syndromes. 2018;78(2):193–201. doi: 10.1097/QAI.0000000000001653 29767640.

28. Radtke KK, Bacchetti P, Anastos K, Merenstein D, Crystal H, Karim R, et al. Use of Nonantiretroviral Medications That May Impact Neurocognition: Patterns and Predictors in a Large, Long-Term HIV Cohort Study. Journal of acquired immune deficiency syndromes. 2018;78(2):202–8. doi: 10.1097/QAI.0000000000001658 29762344; PubMed Central PMCID: PMCPMC5962283.

29. Ruiz ME. Risks of self-medication practices. Current drug safety. 2010;5(4):315–23. 20615179.

30. Schmidt CO, Kohlmann T. When to use the odds ratio or the relative risk? Int J Public Health. 2008;53(3):165–7. 19127890.

31. Diouf A, Youbong TJ, Maynart M, Ndoye M, Dieye FL, Ndiaye NA, et al. [Non-antiretroviral drugs uses among HIV-infected persons receiving antiretroviral therapy in Senegal: Costs and factors associated with prescription]. Rev Epidemiol Sante Publique. 2017; 65(4):295–300. doi: 10.1016/j.respe.2017.02.001 28502580.

32. Nombela N, Kouadio B, Toure S, Seyler C, Flori YA, Anglaret X. Nonantiretroviral drug consumption by CD4 cell count in HIV-infected adults: a 5-year cohort study in Cote d'Ivoire. Journal of acquired immune deficiency syndromes. 2006;41(2):225–31. doi: 00126334-200602010-00015 [pii]. 16394856.

33. Sander LD, Newell K, Ssebbowa P, Serwadda D, Quinn TC, Gray RH, et al. Hypertension, cardiovascular risk factors and antihypertensive medication utilisation among HIV-infected individuals in Rakai, Uganda. Trop Med Int Health. 2015;20(3):391–6. doi: 10.1111/tmi.12443 25430847; PubMed Central PMCID: PMCPMC4308448.

34. Peltzer K, Friend-du Preez N, Ramlagan S, Fomundam H, Anderson J. Traditional complementary and alternative medicine and antiretroviral treatment adherence among HIV patients in Kwazulu-Natal, South Africa. Afr J Tradit Complement Altern Med. 2009;7(2):125–37. 21304624; PubMed Central PMCID: PMCPMC3021154.

35. Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep. 2010;7(2):69–76. doi: 10.1007/s11904-010-0041-9 20425560.

36. Work Group for HIV, Aging Consensus P. Summary report from the Human Immunodeficiency Virus and Aging Consensus Project: treatment strategies for clinicians managing older individuals with the human immunodeficiency virus. J Am Geriatr Soc. 2012;60(5):974–9. doi: 10.1111/j.1532-5415.2012.03948.x 22568508.

37. OMS. Global update on HIV treatment 2013: results, impact and opportunities. 2013. [cited 2018 Jan 21]. Available from: http://apps.who.int/iris/bitstream/10665/85326/1/9789241505734_eng.pdf.

38. OMS. Lignes directrices combinées sur l’utilisation des antirétroviraux pour le traitement et la prévention de l’infection à VIH: résumé des principales caractéristiques et recommandations Juin 2013 2013. [cited 2018 Jan 21]. Available from: http://apps.who.int/iris/bitstream/10665/85324/1/WHO_HIV_2013.7_fre.pdf.

39. OMS. Stratégie de l’OMS pour la Médecine Traditionnelle pour 2002–2005. 2002. [cited 2019 March 21]. Available from: http://apps.who.int/medicinedocs/pdf/s2298f/s2298f.pdf.

40. Tayebati SK, Nittari G, Mahdi SS, Ioannidis N, Sibilio F, Amenta F. Identification of World Health Organisation ship's medicine chest contents by Anatomical Therapeutic Chemical (ATC) classification codes. Int Marit Health. 2017;68(1):39–45. doi: 10.5603/IMH.2017.0007 28357835.

41. Furler MD, Einarson TR, Walmsley S, Millson M, Bendayan R. Use of complementary and alternative medicine by HIV-infected outpatients in Ontario, Canada. AIDS Patient Care STDS. 2003;17(4):155–68. doi: 10.1089/108729103321619764 12737639.

42. Gimeno-Gracia M, Crusells-Canales MJ, Javier Armesto-Gomez F, Rabanaque-Hernandez MJ. Prevalence of concomitant medications in older HIV+ patients and comparison with general population. HIV clinical trials. 2015;16(3):117–24. doi: 10.1179/1528433614Z.0000000012 25978302.

43. Holtzman C, Armon C, Tedaldi E, Chmiel JS, Buchacz K, Wood K, et al. Polypharmacy and Risk of Antiretroviral Drug Interactions Among the Aging HIV-Infected Population. J Gen Intern Med. 2013. doi: 10.1007/s11606-013-2449-6 23605401.

44. Justice AC, Gordon KS, Skanderson M, Edelman EJ, Akgun KM, Gibert CL, et al. Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. Aids. 2018;32(6):739–49. doi: 10.1097/QAD.0000000000001756 29543653; PubMed Central PMCID: PMCPMC5868488.

45. Krentz HB, Cosman I, Lee K, Ming JM, Gill MJ. Pill burden in HIV infection: 20 years of experience. Antivir Ther. 2012;17(5):833–40. doi: 10.3851/IMP2076 22358155.

46. Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther. 2010;15(3):413–23. doi: 10.3851/IMP1540 20516560.

47. Tseng A, Szadkowski L, Walmsley S, Salit I, Raboud J. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother. 2013;47(11):1429–39. doi: 10.1177/1060028013504075 24285760.

48. Zhou S, Martin K, Corbett A, Napravnik S, Eron J, Zhu Y, et al. Total daily pill burden in HIV-infected patients in the southern United States. AIDS Patient Care STDS. 2014;28(6):311–7. doi: 10.1089/apc.2014.0010 24901464; PubMed Central PMCID: PMCPMC4180528.

49. Furler MD, Einarson TR, Walmsley S, Millson M, Bendayan R. Polypharmacy in HIV: impact of data source and gender on reported drug utilization. AIDS Patient Care STDS. 2004;18(10):568–86. doi: 10.1089/apc.2004.18.568 15630785.

50. Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother. 2011;66(9):2107–11. dkr248 [pii] doi: 10.1093/jac/dkr248 21680580.

51. Brown TT, Guaraldi G. Multimorbidity and Burden of Disease. Interdiscip Top Gerontol Geriatr. 2017;42:59–73. doi: 10.1159/000448544 27875824.

52. Harris TG, Rabkin M, El-Sadr WM. Achieving the fourth 90: healthy aging for people living with HIV. Aids. 2018;32(12):1563–9. doi: 10.1097/QAD.0000000000001870 29762172.

53. Adams JL, Almond ML, Ringo EJ, Shangali WH, Sikkema KJ. Feasibility of nurse-led antidepressant medication management of depression in an HIV clinic in Tanzania. Int J Psychiatry Med. 2012;43(2):105–17. doi: 10.2190/PM.43.2.a 22849034; PubMed Central PMCID: PMCPMC3731063.

54. Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, Gonzalez IJ, et al. Antimicrobial resistance in Africa: a systematic review. BMC infectious diseases. 2017;17(1):616. doi: 10.1186/s12879-017-2713-1 28893183; PubMed Central PMCID: PMCPMC5594539.

Use of non-HIV medication among people living with HIV and receiving antiretroviral treatment in Côte d’Ivoire, West Africa: A cross-sectional study

Souhrn

Background

Methods

Results

Conclusion

Klíčová slova:

Zdroje

PLOS One

Svět praktické medicíny 1/2024 (znalostní test z časopisu)

Koncepce osteologické péče pro gynekology a praktické lékaře

Sekvenční léčba schizofrenie

Hypertenze a hypercholesterolémie – synergický efekt léčby

Význam metforminu pro „udržitelnou“ terapii diabetu